Showing results (81-90 of 88) with videos related to
Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
The Journal of Biological Chemistry|October 13, 2011
Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptorChristoph Garbers, Wolfgang Thaiss, Gareth W Jones, et al.Journal of Leukocyte Biology|June 25, 1999
Depletion of eosinophils in mice through the use of antibodies specific for C-C chemokine receptor 3 (CCR3)J C Grimaldi, N X Yu, G Grunig, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 28, 2010
Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunityRami Lissilaa, Vanessa Buatois, Giovanni Magistrelli, et al.Annals of the Rheumatic Diseases|December 25, 2015
Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritisMarc Corbera-Bellalta, Ester Planas-Rigol, Ester Lozano, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 25, 2010
ADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conferenceA Davenport, S D Anker, A Mebazaa, et al.Journal of Immunology (Baltimore, Md. : 1950)|January 21, 2014
Anti-CD79 antibody induces B cell anergy that protects against autoimmunityIan R Hardy, Nadia Anceriz, François Rousseau, et al.Cancer Immunology Research|January 6, 2025
NI-3201 Is a Bispecific Antibody Mediating PD-L1-Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor ControlSara Majocchi, Pauline Lloveras, Lise Nouveau, et al.Molecular Cancer Therapeutics|May 11, 2018
Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and LeukemiaVanessa Buatois, Zoë Johnson, Susana Salgado-Pires, et al.Pageof 9